Sling Therapeutics Appoints Ken Lock as Chief Commercial Officer
18 Jun 2025 //
BUSINESSWIRE
Sling`s oral Tepezza rival hits goal in thyroid eye disease, Ph 3
15 Jan 2025 //
PR NEWSWIRE
Sling To Present Ph 2b/3 Linsitinib Results For Thyroid Eye Disease
13 Jan 2025 //
PR NEWSWIRE